Celmatix, Inc. Release: Study Indicates Cystic Fibrosis Carrier Status In Females Not A Factor In IVF Success

NEW YORK, NY--(Marketwired - October 30, 2014) -

Highlighted Links

Celmatix

Female cystic fibrosis mutation carriers and assisted reproductive technology

Celmatix, a privately held personalized medicine company focused on maximizing lifelong fertility, today announced publication of a study evaluating the possible association between cystic fibrosis (CF) carrier status in females and in vitro fertilization (IVF) response and outcomes. The paper appears in the November issue of Fertility and Sterility and is titled "Female cystic fibrosis mutation carriers and assisted reproductive technology: Does carrier status affect reproductive outcomes?”

The study examined females under 40 who were screened for cystic fibrosis mutations and received IVF treatment between July 2002 and March 2013. The retrospective cohort study found no significant differences in stimulation response or cycle outcomes between female CF mutation carriers and noncarriers.

"We are committed to uncovering how a woman's unique DNA signature impacts her fertility in order to help patients and doctors make better treatment decisions," said Dr. Piraye Yurttas Beim, Founder and CEO, of Celmatix. "Research like this moves us one step closer to that vision of leveraging personalized data for improving fertility planning and outcomes."

"Our team is encouraged by these findings and can now reassure female CF mutation carriers that their carrier status is unlikely to affect their chances of getting pregnant with IVF," said Dr. Alan B. Copperman, a Founding Partner of Reproductive Medicine Associates of New York. "Further research is needed to determine whether the subtle differences noted among carriers of specific CF mutation loci are clinically relevant and whether CF mutation carrier status in females may impact reproductive outcomes outside the context of assisted reproductive technologies (ART)."

About Celmatix, Inc.
Founded in 2009, Celmatix is a New York City-based personalized medicine company focused on maximizing lifelong fertility. By leveraging innovations in genomics, data science, and information technology, Celmatix is creating products that help personalize the treatment for infertility and fertility planning. Celmatix's key research discoveries include powerful predictive models that can calculate personalized chances for success for different treatment options across multiple cycles and the identification of Fertilome™DNA, the regions of the human genome that are most likely to influence a woman's fertility potential. For more information, visit www.celmatix.com.

About Reproductive Medicine Associates of New York
Reproductive Medicine Associates of New York (RMA of New York) is a national and international leader in state-of-the-art, compassionate reproductive medicine. The integrated team of physicians and scientists at RMA of New York has extensive experience and training in reproductive endocrinology, fertility and urology, and consistently reports high success rates to the Society for Assisted Reproductive Technology (SART) and the Centers for Disease Control and Prevention (CDC). RMA of New York's achievements in the treatment of infertility have been internationally recognized, and the group maximizes access to care by assisting patients in exploring all available insurance coverage and financing options. RMA of New York is sensitive to the needs of the LGBT community, women choosing single or same-sex motherhood, and women pursuing fertility preservation for elective indications as well as those in need of oncofertility services. Headquartered on the Upper East Side of Manhattan, RMA of New York has patient care facilities in Lower Manhattan, Brooklyn, Garden City, White Plains and Cornwall, NY. Additionally, RMA of New York has patient care facilities in Mexico City, Mexico. For more information, visit www.rmany.com.